MDxHealth SA is seeking shareholder approval at an extraordinary general meeting on November 19, 2026, for a share consolidation (reverse stock split) with a ratio between 1-for-5 and 1-for-30. The board will determine the final ratio within this range and implement the split within six months of approval. This action aims to address Nasdaq listing compliance requirements by increasing the per-share price. MDxHealth SA develops and markets non-invasive diagnostic tests for colorectal cancer.
